Infectious Diseases Research Collaboration
Kampala, PO Box 7475, Uganda
NCT Number: NCT02009215
We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Dihydroartemisinin-piperaquine (DP) will be administered to schoolchildren monthly for up to six rounds of treatment during one school year. Outcomes will be measured using surveys of communities, schoolchildren, and mosquito vectors. Our proposal also includes health service research to evaluate the potential feasibility of taking the programme to scale, which will guide future research and implementation of the intervention, and help shape policies in Uganda and elsewhere in Africa.
Looking for future studies?
Notify Me5 year and older
All sexes
Interventional
Phase 4
Kampala, PO Box 7475, Uganda
Study objective: The primary objective of the study is to evaluate the impact of IPT for malaria in schoolchildren using monthly DP, as compared with the current standard of care (no IPT), on community-level indicators of malaria transmission. We will test the hypothesis that malaria transmission, as measured by the prevalence of asexual parasitaemia and the entomological inoculation rate (EIR), will be lower in communities surrounding the intervention schools, than those surrounding the control schools.
Study site: The study will be conducted in Jinja district, Uganda.
Clusters: A cluster will be defined as one primary day school plus the 100 closest households surrounding the school. The clusters will be defined prior to randomisation using digitally enumerated maps. We plan to include approximately 84 clusters in the study, with one school per cluster; half will be randomised to the IPT intervention, and half to control.
Randomisation: Randomisation will be conducted by the trial statistician, who is not directly involved in the field activities. Primary schools will be stratified by type of ownership (public vs private). Restricted randomisation will be employed to ensure balance on type of school and geographical location.
Study population: The intervention will be delivered to children attending participating primary schools that are randomised to the intervention group.
The IPT intervention: IPT with dihydroartemisinin-piperaquine (DP) will be delivered to all schools located in the intervention clusters. Treatment will be administered to participating students monthly, for up to 6 rounds of IPT during one school year, and will not be blinded.
Administration of DP: All enrolled students will receive DP (Duo-cotexcin, Holley Cotec Pharmaceuticals) given once a day for 3 consecutive days. DP will be dosed according to weight-based guidelines. Full-strength DP tablets (40/320mg) will be administered orally by study personnel, and all treatments will be directly observed.
Evaluation procedures: Outcomes will be measured through surveys of communities, schoolchildren, and mosquito vectors. In addition, the safety of IPT with monthly DP, and the potential feasibility of the IPT intervention will also be assessed.
Analytical plan
For binary outcomes, generalised linear Poisson models with log link function will be used. The effect of the intervention will be quantified by calculation of a prevalence risk ratio. For quantitative outcomes, linear regression models will be used. The effect of the intervention will be quantified by calculation of difference in mean outcome. Rate ratios will be used to describe the effect of the intervention on rates. An estimate of the coefficient of variation, k, will be provided overall and for the community survey for each age group (as defined by the stratified sampling).
The probability of selection for the final community survey was related to the sampling frame which was determined by the expected parasite prevalence (which varies by age) in age categories; < 5 years, 5-15 years, > 15 years. Therefore, the age structure of the study population is not representative of the community population as a whole. Because we are looking at the community effect we will use inverse probability weights based on the age population structure of all clusters as recorded by the census survey. In practice, each individual will be assigned one of three weights, generated using the census survey, and based on their age as recorded at the final community survey. Population estimates of prevalence will be obtained using svy commands with the cluster as the primary sampling unit and age-related inverse probability weights. Children selected for the school survey were randomly selected after stratification by class. Households selected for the entomological survey were also randomly selected. No weighting is therefore required for the analysis of either the school or entomological surveys.
The effect of the intervention will also be assessed using adjusted analyses. The cluster-specific prevalence or mean from the baseline survey will be adjusted for where available. Variables collected in the baseline community survey, which were imbalanced between trial arms, and likely to be prognostic for outcomes will be adjusted for. Secondary analyses will be conducted to assess whether the effect of the intervention differs by age group or school type. The effect of the intervention for each outcome will be examined by age group or school type and tests for interaction conducted.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
For IPT intervention
Inclusion criteria
Exclusion criteria
Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
Other names: Duo-cotecxin
Time frame: Approximately 1-4 months after completion of the intervention
Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy.
Time frame: Over approximately 1 year
EIR will be defined as the number of infectious bites per person per year (the human biting rate multiplied by the sporozoite rate).
Time frame: During the final 1 month of the intervention
Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy.
Time frame: Approximately 1-4 months after completion of the intervention
Proportion of samples that are positive for asexual parasites by microscopy and LAMP
Time frame: Approximately 1-4 months after completion of the intervention
Proportion of haemoglobin measurements categorised as mild, moderate, and severe anaemia according to WHO age-stratified guidelines, in children under five
Time frame: Approximately 1-4 months after completion of the intervention
Proportion of thick blood smears that are positive for sexual parasites
Time frame: Over approximately 1 year
Proportion of An gambiae infected with sporozoites
Time frame: Over approximately 6 months, during the delivery of the intervention
Proportion of children enrolled in the intervention experiencing any SAEs out of the total number of children enrolled; collected during prospective monitoring
London School of Hygiene and Tropical Medicine
Other
'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial
Acronym: START-IPT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT05891236
Infections, Malaria
Baltimore, Maryland, United States
View Trial DetailsNCT07060508
Infections, Malaria
Faladié, Koulikoro, Mali
View Trial DetailsNCT04529434
Diarrhoea;Acute, Infections
Dar Es Salaam, Mtwara, Tanzania
View Trial Details